Calidi Biotherapeutics(Cldi) Financials: Payables Turnover Compared To Industry Average, Plus Other Key Ratios
Growth Trend (Last 5 Years)
Growth - payables turnover
This chart shows the historical trend of payables turnover for CLDI compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Payables Turnover
Definition: Payables turnover shows how fast the company pays its suppliers for goods or services bought on credit. A high turnover means the company pays suppliers quickly, which may reflect strong cash flow or favorable terms. A very low turnover might mean the company is stretching payments to preserve cash — or possibly experiencing financial strain.
Interpretation:
• In '2021', CLDI's payables turnover was 0.15, indicating how promptly the company pays its suppliers. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2021' stood at 2.00.
• In '2022', CLDI's payables turnover was 0.01, indicating how promptly the company pays its suppliers. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2022' stood at 2.44. Industry average increased by 0.43 compared to previous year.
• In '2023', CLDI's payables turnover was 0.00, indicating how promptly the company pays its suppliers. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at 2.25. Industry average declined by 0.18 from previous year.
Overall, CLDI's payables turnover has been volatile but showed a downward trend over the past 3 years.
Formula: Payables Turnover = Cost of Goods Sold / Average Accounts Payable
Good Range: Ranges 5-15 depending on industry.